Dishman Pharma is looking at a minimum growth of 30% in the next 2-3 years, according to managing director, JR Vyas. The company will close its $25m acquisition of a European contract manufacturer in mid-February.
India Earnings
Friday, 25 January 2008
Dishman looks for growth and Euro acquisition
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment